Nutley, NJ - An injectable form of ibandronate (Boniva, Roche/GlaxoSmithKline) that can be given once every three months has been approved by the US Food and Drug Administration (FDA) for treatment of ...

WASHINGTON, June 7 (Reuters) - Patients who want an injectable form of Roche Holding AG's bone-strengthening drug Boniva may not be able to get it in the next few weeks because the company did not ...

Many companies have been caught off-guard by the extent to which generic competition has eaten away at their sales. Genentech says it managed to be caught off-guard by a lack of it, leading to a ...

Ibandronate (as sodium) 3mg/3mL; soln for IV inj. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone ...

While drug shortages often are tied to manufacturing interruptions, Roche's ($RHHBY) injectable form of its osteoporosis drug Boniva will be in limited supply for ...

SAN FRANCISCO (MarketWatch) -- Roche and GlaxoSmithKline Plc said late Friday the Food and Drug Administration has approved Boniva Injection, the first intravenous medication for the treatment of ...

Roche announced the results from the first year of a phase III study (DIVA) investigating an intravenous injection of Bonviva/Boniva (ibandronate) with extended intervals between dosages, for the ...

A new treatment for osteoporosis that can be given just once every three months has been approved by the US Food and Drug Administration. A new treatment for osteoporosis that can be given just once ...

Ibandronate (as sodium) 3mg/3mL; soln for IV inj. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone ...

WASHINGTON (Reuters) – Patients who want an injectable form of Roche Holding AG’s bone-strengthening drug Boniva may not be able to get it in the next few weeks because the company did not accurately ...